Tatemitsu Rai Selected Research

Pseudohypoaldosteronism

12/2018	Decreased KLHL3 expression is involved in the pathogenesis of pseudohypoaldosteronism type II caused by cullin 3 mutation in vivo.
1/2018	WNK1 regulates skeletal muscle cell hypertrophy by modulating the nuclear localization and transcriptional activity of FOXO4.
4/2017	WNK4 is an Adipogenic Factor and Its Deletion Reduces Diet-Induced Obesity in Mice.
1/2017	Impaired degradation of medullary WNK4 in the kidneys of KLHL2 knockout mice.
1/2017	KLHL3 Knockout Mice Reveal the Physiological Role of KLHL3 and the Pathophysiology of Pseudohypoaldosteronism Type II Caused by Mutant KLHL3.
1/2017	WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
11/2015	Involvement of selective autophagy mediated by p62/SQSTM1 in KLHL3-dependent WNK4 degradation.
11/2015	Impaired degradation of WNK by Akt and PKA phosphorylation of KLHL3.
10/2015	Generation and analysis of knock-in mice carrying pseudohypoaldosteronism type II-causing mutations in the cullin 3 gene.
9/2015	Kelch-Like Protein 2 Mediates Angiotensin II-With No Lysine 3 Signaling in the Regulation of Vascular Tonus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tatemitsu Rai Research Topics

Disease

24	Pseudohypoaldosteronism 12/2018 - 10/2006
12	Hypertension (High Blood Pressure) 01/2020 - 10/2006
9	Chronic Renal Insufficiency 05/2021 - 03/2012
6	Hyperkalemia 01/2020 - 07/2005
4	Renal Insufficiency (Renal Failure) 01/2021 - 01/2016
4	Nephrogenic Diabetes Insipidus 12/2018 - 09/2006
3	Fibrosis (Cirrhosis) 05/2021 - 10/2017
3	Hypokalemia 01/2019 - 10/2009
3	Alkalosis 01/2019 - 10/2009
3	Hypertrophy 01/2018 - 04/2005
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2017 - 06/2013
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2021 - 06/2013
2	Bartter Syndrome (Syndrome, Bartter) 01/2021 - 01/2019
2	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2021 - 11/2013
2	Bacteremia 06/2019 - 11/2018
2	Brain Diseases (Brain Disorder) 06/2019 - 01/2015
2	Diabetes Mellitus 01/2018 - 01/2018
2	Sarcopenia 01/2018 - 01/2017
2	Multiple Myeloma 10/2017 - 01/2016
2	Sarcoidosis (Schaumann Disease) 11/2015 - 11/2013
2	Acidosis 10/2014 - 10/2006
2	Dehydration (Water Stress) 12/2008 - 08/2005
2	Acute Kidney Injury (Acute Renal Failure) 08/2006 - 12/2005
2	Ischemia 08/2006 - 12/2005
1	Inflammation (Inflammations) 05/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Acute Tubulointerstitial Nephritis 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021
1	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 01/2021
1	Sepsis (Septicemia) 12/2020
1	Myasthenia Gravis 06/2019
1	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2019
1	Polyuria 01/2019
1	Infections 11/2018
1	Infected Aneurysm 11/2018
1	Muscular Atrophy (Muscle Atrophy) 01/2018
1	Atrophy 01/2018

Drug/Important Bio-Agent (IBA)

22	Phosphotransferases (Kinase)IBA 01/2020 - 10/2006
15	Lysine (L-Lysine)FDA Link 01/2020 - 12/2008
8	Proteins (Proteins, Gene)FDA Link 01/2018 - 06/2002
6	SodiumIBA 01/2020 - 10/2012
6	SaltsIBA 01/2020 - 08/2012
6	Proline (L-Proline)FDA Link 01/2020 - 10/2012
6	Alanine (L-Alanine)FDA Link 01/2020 - 10/2012
4	PotassiumIBA 01/2020 - 07/2005
3	DiureticsIBA 01/2021 - 01/2016
3	Sodium Chloride SymportersIBA 01/2020 - 01/2018
3	AntibodiesIBA 06/2019 - 11/2013
3	ChloridesIBA 01/2019 - 12/2015
3	Vasopressins (Vasopressin)IBA 01/2019 - 11/2016
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 11/2015 - 09/2013
3	Aquaporin 2IBA 06/2013 - 09/2006
3	Glycerol (Glycerine)FDA LinkGeneric 08/2006 - 04/2005
2	Fibrinogen (Factor I)FDA Link 06/2019 - 06/2017
2	Immunoglobulin G (IgG)IBA 06/2019 - 06/2017
2	Factor XIII (Coagulation Factor XIII)IBA 06/2019 - 06/2017
2	Member 3 Solute Carrier Family 12IBA 01/2019 - 11/2015
2	Cullin Proteins (Cullins)IBA 12/2018 - 10/2015
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2018 - 01/2017
2	Bortezomib (Velcade)FDA Link 10/2017 - 01/2016
2	Aquaporins (Water Channels)IBA 06/2013 - 12/2009
2	Triglycerides (Triacylglycerol)IBA 12/2012 - 04/2005
2	Cisplatin (Platino)FDA LinkGeneric 08/2006 - 12/2005
2	Biomarkers (Surrogate Marker)IBA 08/2006 - 12/2005
1	Prostaglandin D2IBA 05/2021
1	EnzymesIBA 05/2021
1	LipidsIBA 05/2021
1	Collagen Type I (Type I Collagen)IBA 05/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	CytokinesIBA 12/2020
1	SEA 0400IBA 01/2020
1	sodium-calcium exchanger 1IBA 01/2020
1	Cephalosporins (Cephalosporin Antibiotics)IBA 06/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2019
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 06/2019
1	Third Generation CephalosporinsIBA 06/2019
1	Cholinergic ReceptorsIBA 06/2019
1	Tryptophan (L-Tryptophan)FDA Link 06/2019
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2019
1	Calcineurin InhibitorsIBA 01/2019
1	Tolvaptan FDA Link 01/2019
1	4- hydroxy- 3- (4- (2- hydroxyphenyl)phenyl)- 6- oxo- 7H- thieno(2,3- b)pyridine- 5- carbonitrileIBA 01/2019
1	Member 1 Solute Carrier Family 12IBA 01/2019
1	Adenosine Monophosphate (AMP)IBA 01/2019
1	Vancomycin FDA LinkGeneric 11/2018
1	Ligases (Synthetase)IBA 01/2018
1	Adenine FDA LinkGeneric 01/2018
1	UbiquitinIBA 01/2018
1	Small Interfering RNA (siRNA)IBA 01/2018
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2018

Therapy/Procedure

5	Renal Dialysis (Hemodialysis) 06/2019 - 02/2011
2	Protein-Restricted Diet (Diet, Protein Restricted) 01/2019 - 03/2012
2	Therapeutics 01/2016 - 07/2013
2	Sodium-Restricted Diet (Diet, Sodium Restricted) 08/2011 - 10/2009
1	Catheters 11/2018